BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 16459265)

  • 21. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
    Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods.
    Smellie WJ; Dean CJ; Sacks NP; Zalutsky MR; Garg PK; Carnochan P; Eccles SA
    Cancer Res; 1995 Dec; 55(23 Suppl):5842s-5846s. PubMed ID: 7493357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.
    Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K
    Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
    Vaidyanathan G; Affleck DJ; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2002 Jan; 29(1):1-11. PubMed ID: 11786270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
    Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M
    Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved iodine radiolabels for monoclonal antibody therapy.
    Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
    Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
    Lindegren S; Frost S; Bäck T; Haglund E; Elgqvist J; Jensen H
    J Nucl Med; 2008 Sep; 49(9):1537-45. PubMed ID: 18703591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
    Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD
    Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.
    Kuan CT; Wikstrand CJ; Archer G; Beers R; Pastan I; Zalutsky MR; Bigner DD
    Int J Cancer; 2000 Dec; 88(6):962-9. PubMed ID: 11093822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Hens M; Vaidyanathan G; Zhao XG; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2010 Oct; 37(7):741-50. PubMed ID: 20870149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer.
    Wilbur DS; Hadley SW; Hylarides MD; Abrams PG; Beaumier PA; Morgan AC; Reno JM; Fritzberg AR
    J Nucl Med; 1989 Feb; 30(2):216-26. PubMed ID: 2738650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate.
    Vaidyanathan G; Affleck DJ; Zalutsky MR
    Bioconjug Chem; 1997; 8(5):724-9. PubMed ID: 9327137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors.
    García-Garayoa E; Maes V; Bläuenstein P; Blanc A; Hohn A; Tourwé D; Schubiger PA
    Nucl Med Biol; 2006 May; 33(4):495-503. PubMed ID: 16720241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
    Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF
    J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. External beam radiation enhances antibody mediated radiocytotoxicity in human glioma cells in vitro.
    Bender H; Emrich JG; Eshelman J; Chu MA; Steplewski Z; Biersack HJ; Brady LW
    Anticancer Res; 1997; 17(3B):1797-802. PubMed ID: 9179236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo targeting of malignant melanoma by 125Iodine- and 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen.
    Kang N; Hamilton S; Odili J; Wilson G; Kupsch J
    Clin Cancer Res; 2000 Dec; 6(12):4921-31. PubMed ID: 11156253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.
    Foulon CF; Welsh PC; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2001 Oct; 28(7):769-77. PubMed ID: 11578897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
    Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
    Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.